Hcw biologics granted extension by the nasdaq hearings panel to regain compliance with continued listing requirements

Miramar, fla., march 06, 2025 (globe newswire) -- hcw biologics inc. (the “company” or “hcw biologics”) (nasdaq: hcwb), a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen healthspan by disrupting the link between inflammation and age-related diseases, today reported that, on march 3, 2025, the nasdaq hearings panel (the “panel”) of the nasdaq stock market llc (“nasdaq” or the “exchange”) granted the company an extension in which to regain compliance with all continued listing rules of the nasdaq capital market.
HCWB Ratings Summary
HCWB Quant Ranking